학술논문
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
Document Type
Article
Author
Voorhees, P.M.; Sborov, D.W.; Laubach, J.; Richardson, P.G.; Kaufman, J.L.; Reeves, B.; Rodriguez, C.; Chari, A.; Silbermann, R.; Costa, L.J.; Anderson, L.D.; Nathwani, N.; Shah, N.; Bumma, N.; Efebera, Y.A.; Holstein, S.A.; Wildes, T.M.; Costello, C.; Jakubowiak, A.; Orlowski, R.Z.; Shain, K.H.; Cowan, A.J.; Dinner, S.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T.S.; Usmani, S.Z.
Source
In: The Lancet Haematology . (The Lancet Haematology, October 2023, 10(10):e825-e837)
Subject
Language
English
ISSN
23523026